A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Overview of attention for article published in Journal of Thoracic Oncology, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 5 news outlets
policy: 1 policy source

twitter: 30 X users
guideline: 5 clinical guideline sources

Readers on

mendeley: 231 Mendeley

So far, Altmetric has seen 32 X posts from 30 X users, with an upper bound of 134,198 followers.

ref from Dr. Julia K Rotow https://t.co/zCBwxaxx3E https://t.co/9KQrsT7eBZ https://t.co/SeS7TCTPA5 https://t.co/COYb4dYbCI

RT @n8pennell: @TumorBoardTues @NatureRevCancer @TonyMok9 @NEJM @JTOonline @FDA @RamalingamMD @JackWestMD @HosseinBorghaei 7/17 #TumorBoard…

RT @JohnEbbenMDPhD: This. Is. Why. We. Try (when possible). To Wait. For. The. NGS. 👏🏼 Hard though when there's a very high PD-L1 TPS that…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 28 additional X posts.